IntelGenx Technologies (IGXT) has released an update.
IntelGenx Technologies Corp., a leader in pharmaceutical films, has announced restructuring under the CCAA to explore strategic alternatives, including a potential sale, recapitalization, or other transactions. The move follows a comprehensive review by the Board, seeking to maximize returns and sustain operations, while the company’s stock trading remains halted pending a TSX suitability review. Interim financing is expected to support IntelGenx through its strategic review and restructuring process.
For further insights into IGXT stock, check out TipRanks’ Stock Analysis page.
